The Foundation for Angelman Syndrome Therapeutics (FAST) has helped redefine the role of advocacy groups. Founded and led by parents, FAST has moved beyond raising awareness to actively fund, ...

KANSAS CITY, Mo. (KCTV) - Four-year-old Maddie loves cheese and fruit snack gummies, being right in the middle of the action, and playing with her twin sister, Kellie, and older brother, Colin. When ...

The Pinball Lounge at 78th Street Sudios offers an ideal setting for this unique fundraiser. The event runs from 4-6 pm, providing families with an accessible Sunday afternoon activity. True to its ...

As it kicks off a pivotal phase 3 trial of its investigational treatment for Angelman syndrome (AS), Ionis Pharmaceuticals is laying the groundwork for a potential launch. After spending the last ...

Ionis Pharmaceuticals, which is developing a treatment for the rare neurological disease of Angelman syndrome (AS), turned to Lifetime Television’s “Behind the Mystery” series to increase public ...

Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by the loss of function of the maternally inherited ubiquitin E3 ligase UBE3A gene. AS is characterized by severe symptoms, ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 for the treatment of Angelman ...

Researchers from Brain Research Institute, Niigata University, Japan have revealed that environment influences social behaviors in autism. By using zebrafish that have a mutation in ube3a, a gene ...

Broken Hill man Mitch McKenny plans to run from the outback city to Newcastle in 29 days. He aims to raise awareness and funds for Angelman syndrome, a rare genetic disorder. ‘Catastrophe’: Watchdog’s ...

Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 “The accelerated ...